跳至主要内容
临床试验/NCT00338260
NCT00338260已完成3 期

A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy

Organon and Co0 个研究点目标入组 496 人开始时间: 1995年6月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
496
主要终点
Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)

研究概览

简要总结

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
55 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 55 to 80 years
  • Males and females
  • Hypertension (160-200/95-115 mm Hg
  • ECG evidence of left ventricular hypertrophy

排除标准

  • Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
  • Myocardial infarction or stroke within 6 months

结局指标

主要结局

Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)

次要结局

  • cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus

研究者

申办方类型
Industry
责任方
Sponsor

相似试验